HD-OPM Archive
Topics › Weight, visceral & liver fat

Semaglutide-driven visceral fat loss slowed epigenetic aging clocks in a 32-week trial

Louis Nervegna · Jun 13, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
Weight, visceral & liver fatAging & longevityGLP-1 drugs (semaglutide, tirzepatide)
AI summary & key facts

Louis highlights a FoundMyFitness note that in a 32-week semaglutide trial in adults with excess visceral fat, multiple epigenetic aging clocks showed improvement. The proposed mechanism is less adipose-driven inflammatory and metabolic signaling.

Reducing visceral fat may fundamentally slow aging, especially in people who are obese.

#visceralfatHD #horvathHD #epigeticclockHD #agingHD #longevityHD #inflammationHD #liverfatHD #glp1HD #semaglutideHD #weightlossHD #obesityHD

Research cited

Major weight loss clearly and strongly slows biological aging

In an analysis of a 32-week GLP-1 agonist (semaglutide) trial in adults with excess visceral fat, multiple epigenetic aging clocks picked up the improvement

The likely mechanism: less visceral fat means less adipose-driven inflammatory and metabolic signaling that can accelerate aging biology

That fits a hard truth about obesity: it actively pushes aging biology in the wrong direction, raising risk for cardiovascular disease, type 2 diabetes, cancer, and shorter life expectancy

_

New episode with Dr. Steve Horvath out now

Watch it here:

▶Video · YouTube · FoundMyFitnessThe 7 Habits of People Who Age Slower | Dr. Steve HorvathThe strongest anti-aging strategy may be less about dramatic reversal and more about removing what accelerates aging in the first place. In this episode, Dr. Steve Horvath maps out the science behind biological age and how aging clocks are changing the way researchers evaluate longevity interventions. He also explains why omega-3s, a daily multivitamin, and…youtube.com
← newer: Dapagliflozin linked to lower heart failure risk in carriersolder: Lyon Heart Study: Mediterranean diet cut cardiac events 73% →